Molbio Diagnostics Initial Public Offering Closes Today 12 August 2026: Last Day to Apply for Mainboard Medical Diagnostics IPO

Molbio Diagnostics initial public offering: LAST DAY 12 Aug 2026. Sub 10-12 Aug. NSE/BSE mainboard. Medical diagnostics. Apply via ASBA/UPI before close today.

The Molbio Diagnostics initial public offering is open for subscription on 12 August 2026, with bidding running from 10 August 2026 to 12 August 2026. Today is the last day to apply for the Molbio Diagnostics initial public offering, making it time-sensitive for investors who wish to participate. The Molbio Diagnostics initial public offering gives retail and institutional investors an opportunity to subscribe to shares of Molbio Diagnostics before the company lists on NSE and BSE (Mainboard). All applications for the Molbio Diagnostics initial public offering must be submitted through the ASBA mechanism or UPI-linked demat accounts before the close of bidding on 12 August 2026.

Molbio Diagnostics is a medical diagnostics company known for rapid molecular diagnostic solutions including point-of-care testing for infectious diseases. The Molbio Diagnostics initial public offering represents Molbio Diagnostics’s entry into the public capital markets. India’s IPO market in August 2026 is active with multiple offerings open simultaneously, and the Molbio Diagnostics initial public offering is one of the offerings investors tracking the primary market should evaluate carefully this week. The Medical Diagnostics sector background of the Molbio Diagnostics initial public offering and the company’s financial profile disclosed in the draft red herring prospectus are the key parameters for evaluating whether to apply for the Molbio Diagnostics initial public offering.

Click Here – Get Free Investment Predictions

What Is the Molbio Diagnostics initial public offering?

The Molbio Diagnostics initial public offering is a public equity offering that invites investors to subscribe to shares of Molbio Diagnostics at the price determined through the book-building or fixed price process as specified in the prospectus. The Molbio Diagnostics initial public offering is listed on NSE and BSE (Mainboard) and regulated by SEBI. Proceeds from the Molbio Diagnostics initial public offering will be used by Molbio Diagnostics as outlined in the DRHP filed with SEBI, typically for business expansion, working capital, and general corporate purposes.

Investors evaluating the Molbio Diagnostics initial public offering should review the company’s revenue growth, profitability track record, debt levels, promoter background, and competitive position in the Medical Diagnostics industry. The Molbio Diagnostics initial public offering valuation at the issue price should be compared to listed peers in the Medical Diagnostics space to assess whether the offering is attractively priced. All relevant data for evaluating the Molbio Diagnostics initial public offering is available in the DRHP filed on the SEBI EDGAR portal.

Molbio Diagnostics initial public offering: How to Apply

To apply for the Molbio Diagnostics initial public offering, investors should log into their broker’s trading platform or bank’s net banking portal and navigate to the current IPO section. Select the Molbio Diagnostics listing, enter the number of lots you wish to bid for, and confirm the bid price as specified in the Molbio Diagnostics initial public offering prospectus. For UPI-based applications for the Molbio Diagnostics initial public offering, enter your registered UPI ID and approve the mandate request within the time allowed by your UPI app. Ensure your demat account is KYC-compliant and linked to an ASBA-enabled bank account before submitting your application for the Molbio Diagnostics initial public offering.

Retail investors applying for the Molbio Diagnostics initial public offering should bid at the cutoff price to maximise their chances of allotment. The minimum lot size for the Molbio Diagnostics initial public offering is specified in the prospectus and represents the smallest number of shares an investor can apply for. Applications for the Molbio Diagnostics initial public offering below the minimum lot size will be rejected. The Molbio Diagnostics initial public offering allotment will be done by lottery among all valid retail applicants if the retail portion is oversubscribed.

Explore Molbio Diagnostics and the Full IPO Calendar on Univest Research Screener

Molbio Diagnostics initial public offering: Grey Market Premium and Subscription Status

Investors tracking the Molbio Diagnostics initial public offering subscription activity should note that Univest does not publish grey market premium figures for the Molbio Diagnostics initial public offering or any other initial public offering. Grey market premium is an unofficial indicator that is not regulated or endorsed by SEBI, NSE, or BSE, and can vary widely between tracker platforms. For grey market premium data on the Molbio Diagnostics initial public offering, investors should refer to dedicated GMP tracking platforms while understanding that such data does not guarantee listing performance.

The Molbio Diagnostics initial public offering subscription status is available on the NSE and BSE websites, which publish live subscription data by investor category (QIB, NII, RII) throughout each day of bidding. High subscription in the QIB and NII categories is generally considered a positive signal for the Molbio Diagnostics initial public offering, though it does not guarantee listing gains. Investors should evaluate the Molbio Diagnostics initial public offering fundamentally and not rely solely on subscription figures or GMP data.

Download the Univest iOS App or Univest Android App to track the Molbio Diagnostics initial public offering and IPO calendar from Univest.

Conclusion

The Molbio Diagnostics initial public offering is open for subscription from 10 August 2026 to 12 August 2026, with Last Day of bidding underway on 12 August 2026. The Molbio Diagnostics initial public offering provides investors with an opportunity to participate in the public listing of Molbio Diagnostics in the Medical Diagnostics sector. Investors should read the prospectus, evaluate the Molbio Diagnostics initial public offering on business fundamentals and valuation, and consult a SEBI-registered financial advisor before applying. Allotment for the Molbio Diagnostics initial public offering will be announced after the subscription window closes on 12 August 2026.

Frequently Asked Questions

What is the Molbio Diagnostics initial public offering?

Ans. The Molbio Diagnostics initial public offering is an initial public offering by Molbio Diagnostics, a Medical Diagnostics company. The Molbio Diagnostics initial public offering is open for subscription from 10 August 2026 to 12 August 2026. Investors can apply for the Molbio Diagnostics initial public offering through the ASBA mechanism or UPI-linked demat accounts. Check the official SEBI EDGAR portal for the complete prospectus and all details of the Molbio Diagnostics initial public offering before subscribing.

What are the subscription dates for the This offering?

Ans. The The public issue subscription window is open from 10 August 2026 to 12 August 2026. Today is the last day to apply for the The issue. Investors who wish to participate in the This public offering must submit their applications through ASBA or UPI before the close of bidding on 12 August 2026. Late applications will not be accepted for the The subscription.

What is the grey market premium for the This listing?

Ans. Univest does not publish grey market premium figures. Grey market premium is an unofficial and unregulated indicator collected informally outside the stock exchanges. It is not published, verified or endorsed by SEBI, NSE or BSE, can vary widely between trackers, and is not always accurate. For grey market premium data, refer to dedicated GMP tracker platforms and exercise caution when using such information for investment decisions related to any initial public offering.

How can I apply for the This offering?

Ans. Investors can apply for the The public issue through ASBA by logging into their bank’s net banking or broker trading platform and selecting the Molbio Diagnostics IPO. For UPI-based applications for the The issue, enter your UPI ID during the application and approve the mandate request within the stipulated time. Apply at the cutoff price to maximise allotment chances in the This public offering.

What categories of investors can apply for the The subscription?

Ans. The This listing is open to Retail Individual Investors (RII), Non-Institutional Investors (NII/HNI), and Qualified Institutional Buyers (QIB) in their respective reservation categories. Retail investors can apply for the This offering up to a maximum of Rs 2 lakh per application. Check the The public issue prospectus for exact lot size and per-category application limits.

What are the key risks of investing in the The issue?

Ans. Key risks of the This public offering include limited post-listing liquidity typical of smaller public offerings, sector-specific challenges in the Medical Diagnostics space, valuation uncertainty at the issue price relative to listed peers, and general market risk. The The subscription is not a guaranteed profit opportunity. Read the DRHP risk factors carefully and consult a SEBI-registered advisor before investing.

When is the allotment date for the This listing?

Ans. The allotment date for the This offering will be announced after the subscription window closes on 12 August 2026. Allotment for the The public issue is typically completed within 6 working days of the close of subscription. Investors can check their The issue allotment status on the BSE or NSE website using their application number or PAN after the announced allotment date.